46 terminated. 46 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 46 | Terminated 46 |
| Phase 2 | 13 | Terminated 13 |
Follow Hepatitis: new trials by email Literature Review of Hepatitis trials Research Report on Hepatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 YS-HBV-002 - Chronic Hepatitis B | Phase 1 | Terminated | Yisheng Biopharma (Singapore) Pte. Ltd. | 16 | 2024-07-01 | 2025-02-24 |
| A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection 162, Placebo - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Yangshengtang Co., Ltd | 1 | 2024-06-03 | 2024-07-16 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection RO7565020, Placebo, Nucleos(t)ide analogue (NUC) treatment - Chronic Hepatitis B | Phase 1 | Terminated | Hoffmann-La Roche | 60 | 2023-04-28 | 2026-01-22 |
| A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects ALG-125755, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 57 | 2022-10-07 | 2024-03-15 |
| A Single and Multiple Ascending Dose Study of JNJ-64457744 JNJ-64457744, Placebo, Tenofovir Disoproxil Fumarate (TDF) - Healthy, Hepatitis B, Chronic | Phase 1 | Terminated | Janssen Research & Development, LLC | 60 | 2022-07-04 | 2025-02-03 |
| Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 74 | 2022-04-14 | 2026-10-14 |
| Ethnobridging Study in Healthy Volunteers, Chinese and Japanese Subjects ATI-2173 50 mg - Chronic Hepatitis b | Phase 1 | Terminated | Antios Therapeutics, Inc | 37 | 2022-03-29 | 2022-11-18 |
| A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects ALG-020572, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 40 | 2021-09-25 | 2023-04-25 |
| A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION. EDP-721, Placebo (Part 1), EDP-721 (Part 2) - Chronic Hepatitis B Virus Infection | Phase 1 | Terminated | Enanta Pharmaceuticals, Inc | 26 | 2021-08-02 | 2022-02-14 |
| Safety, Tolerability, and Pharmacokinetics of AB-836 in Healthy Subjects and Subjects With Chronic HBV Infection AB-836, Placebo, Nucleos(t)ide Analogue - Chronic Hepatitis | Phase 1 | Terminated | Arbutus Biopharma Corporation | 110 | 2021-06-25 | 2022-11-21 |
| Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | Sunshine Lake Pharma Co., Ltd. | 52 | 2020-10-09 | 2024-06-24 |
| A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects ALG-010133, Placebo - Chronic Hepatitis B | Phase 1 | Terminated | Aligos Therapeutics | 103 | 2020-08-17 | 2022-03-15 |
| Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Orencia® (Abatacept) - Autoimmune Hepatitis | Phase 1 | Terminated | Stuart Knechtle, M.D. | 1 | 2020-03-09 | 2021-11-29 |
| Trial of Antibody Responses by Vitamin Supplementation Vitamin A supplementation, No vitamin A supplementation - Healthy Participants | Phase 1 | Terminated | St. Jude Children's Research Hospital | 22 | 2019-08-19 | 2025-09-05 |
| Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation - Hepatitis B, Chronic | Phase 1 / Phase 2 | Terminated | GlaxoSmithKline | 236 | 2019-03-28 | 2026-02-20 |
| A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection RO7239958, Placebo - Hepatitis B Virus Infection | Phase 1 | Terminated | Hoffmann-La Roche | 55 | 2018-12-14 | 2021-05-11 |
| A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection AL-611, Placebo - Hepatitis C | Phase 1 | Terminated | Alios Biopharma Inc. | 24 | 2017-07-07 | 2017-10-25 |
| Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers AL-3778, Entecavir, Tenofovir disoproxil fumarate - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alios Biopharma Inc. | 54 | 2017-01-31 | 2017-10-16 |
| A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection ALN-HBV, Sterile Normal Saline (0.9% NaCl) - Hepatitis B, Chronic Hepatitis B | Phase 1 | Terminated | Alnylam Pharmaceuticals | 24 | 2016-06-24 | 2018-09-24 |
| A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) ARC-521 Injection, Placebo, antihistamine - Hepatitis B | Phase 1 | Terminated | Arrowhead Pharmaceuticals | 47 | 2016-06-01 | 2026-01-12 |
Showing 20 of 46. Sign in to see all of them.
Hepatitis B, Chronic (16) · Hepatitis C (15) · Hepatitis C, Chronic (11) · Hepatitis B (8) · Bronchiolitis Obliterans Syndrome (1) · Hepatitis D (1) · Hepatitis, Alcoholic (1) · Hepatitis, Autoimmune (1) · Hepatitis, Chronic (1) · Liver Diseases (1)
Digestive System Diseases (46) · Liver Diseases (45) · Hepatitis, Viral, Human (42) · Infections (42) · Virus Diseases (42) · Blood-Borne Infections (41) · Communicable Diseases (41) · Chronic Disease (28) · Disease Attributes (28) · Hepatitis, Chronic (28) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · RNA Virus Infections (23) · Flaviviridae Infections (22)
entecavir (5) · Tenofovir (4) · Ribavirin (3) · peginterferon alfa-2b (2) · Abatacept (1) · Acetaminophen (1) · Dosage Forms (1) · Drug Implants (1) · GSK2485852 (1) · Histamine Antagonists (1) · Hydroxychloroquine (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Interferon-alpha (1) · Interleukin-2 (1) · MK-8325 (1)
GlaxoSmithKline (4) · Merck Sharp & Dohme LLC (4) · Aligos Therapeutics (3) · Alios Biopharma Inc. (3) · Hoffmann-La Roche (3) · Alnylam Pharmaceuticals (1) · Antios Therapeutics, Inc (1) · Anza Therapeutics, Inc. (1) · Arbutus Biopharma Corporation (1) · Arrow Therapeutics (1) · Arrowhead Pharmaceuticals (1) · Bader, Ted, M.D. (1) · BioLineRx, Ltd. (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · CureTech Ltd (1)
New Zealand (14) · United States (12) · Hong Kong (8) · United Kingdom (8) · South Korea (6) · Taiwan (6) · Australia (5) · Thailand (5) · France (4) · Poland (4) · Belgium (3) · China (3) · Moldova (3) · Spain (3) · Bulgaria (2)
Brian Murphy, MD, MPH (1) · Brian Sanderson (1) · Chia-Yen Dai, M.D., M.S. (1) · David Mutimer (1) · Edward Gane (1) · Ike Minerva, MD (1) · Kendall A Smith, MD (1) · Marc Bourliere, MD (1) · Mark Holodniy, M.D. (1)
PMID 24041792, PMID 24995515, PMID 27137491, PMID 37290591, PMID 40118118, PMID 41186228, PMID 41571028
2009 (1), 2017 (1), 2018 (1), 2023 (1), U01AI048224 (1)